社区人群痛风危险因素的病例对照研究

目的 探讨社区人群(20岁以上)痛风的危险因素。方法 采用1：3病例对照研究方法，进行单因素与多因素与多因素logistic回归分析。结果 经单因素筛选和多因素分析，在P=0．05水平，高尿酸(OR=8．601)、肥胖(OR=2．910)、伴有高血压病史(OR=2．330)是痛风的独立危险因素。结论 痛风是一种在遗传基础上的与环境和生活方式有关的疾病，改变生活方式、控制相关疾病可能预防或减少高尿酸血症的发生，进而减少痛风的发生。     

Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized,double-blind pilot study

Flavocoxid (Limbrel), a proprietary mixture of flavonoid molecules (baicalin and catechin), was tested against a traditional nonsteroidal anti-inflammatory drug, naproxen, for the management of the signs and symptoms of moderate osteoarthritis (OA) in humans. Discomfort and global disease activity were used as the primary end points, and safety assessments were also taken for both treatments as a secondary endpoint. In this double-blind study, 103 subjects were randomly assigned to receive either flavocoxid [500 mg twice daily (BID)] or naproxen (500 mg BID) in a 1-month onset of action trial. Outcome measures included the short Western Ontario and McMaster University Osteoarthritis Index, subject Visual Analogue Scale for discomfort and global response, and investigator Visual Analogue Scale for global response and fecal occult blood. Both flavocoxid and naproxen showed significant reduction in the signs and symptoms of knee OA (P ≤ .001). There were no statistically detectable differences between the flavocoxid and naproxen groups with respect to any of the outcome variables. Similarly, there were no statistically detectable differences between the groups with respect to any adverse event, although there was a trend toward a higher incidence of edema and nonspecific musculoskeletal discomfort in the naproxen group. In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. A low incidence of adverse events was reported for both groups.     

bFGF和硫糖铝局部应用促扩张术方法研究

目的探讨碱性成纤维细胞生长因子(bFGF)不同剂量、用药方法对扩张组织的影响.方法以白色家猪为实验动物,采用持续恒压扩张技术,观察不同剂量和不同给药时间,bFGF和硫糖铝对扩张组织的影响及组织结构变化.结果扩张术同时每日2次局部应用bFGF 9AU/cm2 硫糖铝100μg/ml,共7 d,浸于明胶海绵上缓慢持续释放对扩张组织的影响最明显,效果最佳,扩张器内实际注液量、扩张所获得的皮肤净增面积明显增加,皮瓣回缩率降低.表皮细胞层数增多,胶原纤维、弹力纤维、成纤维细胞密度和毛细血管密度显著增高.药量增加效果未随之增加.结论持续恒压扩张术时合用bF-GF 9AU/cm2 硫糖铝100μg/ml,每日2次注药浸入明胶海绵持续缓慢释放效果最佳.     

氨溴索对慢性阻塞性肺疾病大鼠模型肺的保护作用

①目的　探讨氨溴索对肿瘤坏死因子α(TNF α)在慢性阻塞性肺疾病 (COPD)大鼠模型肺内表达与分布的影响以及肺泡Ⅱ型上皮细胞超微结构的影响。②方法　实验大鼠随机分为 3组 :健康对照组 (n =8) ,COPD模型组 (n =1 2 ) ,氨溴索干预组 (n =1 2 )。采用熏吸香烟并气管内注入脂多糖法建立大鼠COPD模型 ,氨溴索干预组于COPD模型开始建立时腹腔注射氨溴索溶液 4 0mg/ (kg·d) ,连续 4 0d。观察各组气道炎症的病理特点、超微结构特点、血气指标、肺泡平均内衬间隔、平均肺泡数。应用原位杂交法检测TNF α基因表达的相对含量。③结果　所建COPD模型的病理以及病理生理学改变符合人类COPD的特点。氨溴索干预组肺泡平均内衬间隔、平均肺泡数、TNF α表达强度与健康对照组、COPD模型组比较差异有显著性 (F =3.2 4～ 1 1 .1 1 ,q =4 .74～ 36 .2 2 ,P <0 .0 1 ) ;动脉血氧分压、二氧化碳分压差异亦有显著性 (F =3.30、8.79,q =3.5 0～ 8.6 9,P <0 .0 5 )。 ④结论　长期应用氨溴索对COPD大鼠模型气道炎症有明显的抑制作用     

碱性成纤维细胞生长因子在实验性硬脑膜重建中的应用

[目的] 探讨碱性成纤维细胞生长因子( bFGF)在实验性自体筋膜硬脑膜重建中的应用价值.[方法]取 SD大鼠 35只,分成 5组.其中 A组 3只,直接将背部筋膜覆盖在硬膜外, B组 5只,采用自体筋膜硬脑膜重建模型,通过免疫组织化学方法观察这两组大鼠自体筋膜硬脑膜移植的愈合过程及细胞因子 bFGF在其中的表达; C组、 D组、 E组各 9只,分别进行自体筋膜硬脑膜重建, D组加用外源性 bFGF, E组仅用明胶海绵,通过脑脊液漏研究、免疫组织化学方法研究外源性 bFGF对自体筋膜重建硬脑膜愈合过程的影响并用 RT- PCR方法研究内源性 bFGF mRNA的表达情况.[结果] 大鼠自体筋膜移植硬脑膜部位 bFGF表达明显; C、 D、 E组大鼠重建硬脑膜抵抗脑脊液漏压力值( mmH2O)分别为 311± 75, 497± 153, 338± 88,Ⅰ型胶原纤维表达值分别为 4.9± 0.8, 10.9± 1.6, 5.3± 0.9, D组均好于对照组( P< 0.05);内源性 bFGF mRNA的表达没有明显变化.[结论] 在自体筋膜移植硬脑膜的愈合过程中 bFGF可能起了重要的作用;外源性 bFGF处理的大鼠其移植筋膜愈合要好于对照组.     

胰岛素样生长因子-Ⅰ和胰岛素样生长因子结合蛋白-1与妊高征的关系

目的：探讨胰岛素样生长因子 I(IGF-Ⅰ)和胰岛素样生长因子结合蛋白 1(IGFBP—1)与妊高征(PIH)的关系。方法：采用免疫放射法测定50例妊高征孕妇(PIH组)和108例正常孕妇(对照组)的血清 IGF-Ⅰ、IGFBP-1水平，并对其结果进行相关性分析。结果：①妊高征孕妇血清 IGF-Ⅰ水平低于正常孕妇(P<0.05)，且重度妊高征孕妇血清 IGF-Ⅰ水平低于中度和轻度孕妇(P＜0.05，P＜0.01)。②妊高征孕妇血清 IGFBP-1水平高于正常孕妇(P＜0.05)，且重度妊高征孕妇血清 IGFBP-1水平高于中度和轻度孕妇(P＜0.05，P＜0.01)。③两组孕妇血清 IGF-Ⅰ水平与血清 IGFBP-1水平呈负相关(r=-0.386，P＜0.05)。④妊高征孕妇血清 IGF-Ⅰ水平与舒张压呈负相关(r=-0.386，P＜0.05)，血清 IGFBP-1水平与舒张压呈正相关(r=0.632，P＜0.01)。结论：妊高征孕妇血清 IGF-Ⅰ、IGFBP-1水平的高低可反映妊高征的严重程度。     

丹参与雷公藤多甙联合治疗急性坏死性胰腺炎的实验研究

目的　探讨丹参与雷公藤多甙联合应用对急性坏死性胰腺炎 (acutenecrotizingpancreatitis,ANP)的治疗作用。 方法　采用单次过量 2 0 %L 精氨酸 (10 0 0mg/ 10 0g大鼠体重 )皮下注射建立ANP动物模型。测定血清淀粉酶、TNF α、IL 1β水平 ,并观察胰腺组织的病理变化。根据血清淀粉酶、TNF α、IL 1β水平及胰腺组织的变化来评价胰腺炎的严重程度。 结果　大鼠皮下注射过量L 精氨酸后 ,血清淀粉酶、TNF α、IL 1β水平升高 ,胰腺变性坏死。丹参与雷公藤多甙联合治疗ANP ,可显著降低血清淀粉酶、抑制炎症细胞因子的过度生成 ,组织受损程度明显减轻。结论　丹参与雷公藤多甙联合应用对ANP动物模型具有很好治疗效果 ,可能具有临床应用价值     

转移因子口服液佐治小儿单纯性肾病综合征临床研究

目的：观察转移因子口服液佐治小儿单纯性肾病综合征的疗效。方法：将75例诊断为单纯性肾病综合征的患儿随机分为治疗组和对照组,对照组主要采用泼尼松口服治疗,治疗组另加用转移因子口服液治疗。观察两组的感染率、复发率及治疗前后血IgG、IgA水平。结果：治疗组的感染率和复发率明显较低;治疗后血IgG、IgA水平明显提高,与对照组比较差异明显（P〈0.01）。结论：转移因子口服液佐治小儿单纯性肾病综合征可以降低患者的感染率和复发率,提高血IgG和IgA水平,是治疗肾病综合征的有效方法之一。     

影响糖尿病足坏疽愈合的因素及针对性护理研究

目的探讨针对影响糖尿病肢端坏疽患者愈合因素进行针对性的护理。方法在600例糖尿病足坏疽住院患者中随机抽取168例分成2组,根据2组患者血浆蛋白、动脉硬化下肢血流量、微循环障碍程度、患足骨质破坏情况、缺乏糖尿病足坏疽的防治知识进行分析,找出影响愈合的因素,并做好针对性的护理工作。结果168例糖尿病足坏疽患者,下肢血流量、足背动脉搏动及甲襞微循环比较,2组差异有显著性意义(P<0.05);2组足坏疽合并肾病、骨质破坏和血红蛋白改变情况比较,2组差异有显著性意义(P<0.05)。结论根据糖尿病足坏疽患者影响愈合的因素,进行针对性的护理,加快了糖尿病足坏疽患者的愈合速度,同时综合治疗有利于糖尿病足坏疽的早日愈合,可以减少截肢,提高了糖尿病足坏疽患者的生活质量。     

Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS

BACKGROUND: Platelet hyperfunction contributes to acute coronary syndromes (ACS). Thus, we hypothesized that platelet function under high shear stress predicts recurrent ACS during long-term follow-up of ACS patients. PATIENTS AND METHODS: Consecutive ACS patients (n = 208) were prospectively followed-up for an average of 28 months. Platelet function was measured with the platelet function analyzer (PFA-100; Dade Behring, Marburg, Germany) at baseline for collagen/adenosine diphosphate closure times (CADP-CT) and for collagen/epinephrine closure times (CEPI-CT) after infusion of a uniform dose of 250 mg aspirin. RESULTS: Of the conventional risk factors, only the prevalence of diabetes was higher in ACS patients with re-events. However, use of clopidogrel and use of beta blockers were also slightly lower in patients with re-events (P < 0.05). The unadjusted risk hazard ratio (HR) for re-events was 3.3 [95% confidence interval (95% CI): 1.4-7.4; P = 0.005] in those patients with the shortest CADP-CT values (lowest quartile). Similarly, the risk was 2.0-fold higher (95% CI: 1.1-3.6; P = 0.02) in ACS patients with CEPI-CT < 300 s as compared with CEPI-CT >or = 300 s. Inclusion of diabetes, clopidogrel and beta blockers in a multivariate Cox regression model enhanced the predictive value of CEPI-CT (HR: 2.7). Inclusion of von Willebrand factor levels did not alter the HR for recurrent ACS (HR: 2.1; 95% CI: 1.1-5.2; P = 0.03) for CEPI-CT < 300 s, but reduced the HR for CADP-CT (HR: 2.8, 95% CI: 0.8-9.8; P = 0.11). CONCLUSION: Shortened CT values reflect biologically relevant platelet hyperfunction in patients with ACS because they predict recurrent ACS.